Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 48

Sort by

Sort Order Select

Journal Articles

Development of Novel Chimeric Antigen Receptors Targeting the Gamma-Delta (γδ) T-Cell Receptor

Lauren C Cutmore, Norris Lam, Christina Amatya, Katherine A Weissler, Danielle A Natrakul, James N Kochenderfer

Blood (2024) 144 (Supplement 1): 4789.

https://doi.org/10.1182/blood-2024-204126

Published: 2024

Journal Articles

Adoptive Transfer of T Cells Genetically Engineered to Express T-Cell Receptors Targeting Neoantigens Arising from p53 and Ras Hotspot Mutations in Hematologic Malignancies

Kathryn M Cappell, Sanghyun P Kim, Noam Levin, Norris Lam, Christina Amatya, Lauren C Cutmore, Rachel Beyer, Steven A Rosenberg, James N Kochenderfer

Blood (2023) 142 (Supplement 1): 888.

https://doi.org/10.1182/blood-2023-189459

Published: 2023

Journal Articles

Generation of Hinge-Modified Human CD19 Chimeric Antigen Receptor (CAR) T Cells for the Treatment of CD19-Low Leukemia

Victoria M. Giordani, Justin Mirazee, Marie Pouzolles, Mehdi Benzaoui, Chris Daniel Chien, Saliha Majdoul, Sooraj Achar, Adam Kenet, Madison Wahlsten, Gregoire Altan-Bonnet, James N Kochenderfer, Nirali N. Shah, Taisuke Kondo, Naomi Taylor

Blood (2023) 142 (Supplement 1): 6819.

https://doi.org/10.1182/blood-2023-187954

Published: 2023

Journal Articles

T Cells Expressing a Fully-Human Anti-BCMA Chimeric Antigen Receptor with a Heavy-Chain-Only Antigen-Recognition Domain Exhibit Rapid and Durable Activity Against Multiple Myeloma

Lekha Mikkilineni, Elisabet E. Manasanch, Danielle Natrakul, Katherine Weissler, Jennifer N. Brudno, Jennifer Mann, Stephanie L Goff, James C Yang, Norris Lam, Irina Maric, Hao-Wei Wang, Constance M. Yuan, David F. Stroncek, Steven Highfill, Micaela Ganadan, Rashmika Patel, Steven A Rosenberg, James N. Kochenderfer

Blood (2022) 140 (Supplement 1): 7433–7434.

https://doi.org/10.1182/blood-2022-159156

Published: 2022

Journal Articles

Transient Responses and Significant Toxicities Due to Cytopenias and Rashes with Anti-CD30 CAR T Cells for CD30-Expressing Lymphomas: Results of a Phase I Clinical Trial

Jennifer N. Brudno, Jeremiah Karrs, Danielle Natrakul, Nisha Patel, Lekha Mikkilineni, Jennifer Mann, David F. Stroncek, Steven Highfill, Norris Lam, Genevieve C. Fromm, Rashmika Patel, Stefania Pittaluga, James N. Kochenderfer

Blood (2022) 140 (Supplement 1): 12731–12732.

https://doi.org/10.1182/blood-2022-157149

Published: 2022

Journal Articles

Treatment of Patients with T Cells Expressing a Fully-Human Anti-BCMA CAR with a Heavy-Chain Antigen-Recognition Domain Caused High Rates of Sustained Complete Responses and Relatively Mild Toxicity

Lekha Mikkilineni, Elisabet E. Manasanch, Danielle Natrakul, Jennifer N. Brudno, Jennifer Mann, Stephanie L Goff, James C Yang, Norris Lam, Irina Maric, Maryalice Stetler-Stevenson, Hao-Wei Wang, Constance M. Yuan, Tyler Lowe, David F. Stroncek, Steven Highfill, Rashmika Patel, Micaela Ganadan, Steven A Rosenberg, James N. Kochenderfer

Blood (2021) 138 (Supplement 1): 3837.

https://doi.org/10.1182/blood-2021-152688

Published: 2021

Journal Articles

Development of a Bicistronic Anti-CD19/CD20 CAR Construct Including Optimization to Abrogate Retroviral Recombination Events

Norris Lam, Stephanie Choi, Shicheng Yang, Richard Finney, Margaret Cam, Xiaolin Wu, James N. Kochenderfer

Blood (2021) 138 (Supplement 1): 4808.

https://doi.org/10.1182/blood-2021-150865

Published: 2021

Journal Articles

Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy, in Patients with Relapsed and Refractory Multiple Myeloma: Updated Results from Phase 1 CRB-401 Study

Yi Lin, MD PhD, Noopur S. Raje, MD, Jesus G. Berdeja, MD, David S. Siegel, MD PhD, Sundar Jagannath, MD, Deepu Madduri, MD, Michaela Liedtke, MD, Jacalyn Rosenblatt, MD, Marcela V. Maus, MD PhD, Monica Massaro, MPH, Fabio Petrocca, MD, Andrea Caia, MS, Zhihong Yang, PhD, Timothy B. Campbell, MD PhD, Kristen Hege, MD, Nikhil C. Munshi, MD, James N. Kochenderfer, MD

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-134324

Published: 2020

Journal Articles

Deep and Durable Remissions of Relapsed Multiple Myeloma on a First-in-Humans Clinical Trial of T Cells Expressing an Anti-B-Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor (CAR) with a Fully-Human Heavy-Chain-Only Antigen Recognition Domain

Blood (2020) 136 (Supplement 1): 50–51.

https://doi.org/10.1182/blood-2020-138839

Published: 2020

Journal Articles

Infectious Complications Associated with CAR T-Cell Therapy

Lekha Mikkilineni, MD, Shilpa Shahani, MD, Bonnie Yates, NP, Seth M. Steinberg, PhD, Tara Palmore, MD, Veronique Nussenblatt, MD, Daniel W. Lee, MD, Rosandra N. Kaplan, MD, Crystal L. Mackall, MD, Terry J. Fry, MD, Juan Gea-Banacloche, MD, Theresa Jerussi, James N. Kochenderfer, MD, Nirali N. Shah, MD

Blood (2019) 134 (Supplement_1): 4449.

https://doi.org/10.1182/blood-2019-131170

Published: 2019

Journal Articles

T Cells Expressing an Anti-B-Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor with a Fully-Human Heavy-Chain-Only Antigen Recognition Domain Induce Remissions in Patients with Relapsed Multiple Myeloma

Lekha Mikkilineni, MD, Elisabet E. Manasanch, MD, Norris Lam, BS, Danielle Vanasse, BS, Jennifer N. Brudno, MD, Irina Maric, MD MSci, Jeremy J. Rose, MS, Maryalice Stetler-Stevenson, MD PhD, Hao-Wei Wang, MD PhD, Constance M. Yuan, MD PhD, David F. Stroncek, MD, Jennifer Mann, CRNP, Micaela Ganadan, BSN, RN, Rashmika Patel, Nathan Trinklein, PhD, Ben Buelow, MD PhD, Ronald E. Gress, MD, James N. Kochenderfer, MD

Blood (2019) 134 (Supplement_1): 3230.

https://doi.org/10.1182/blood-2019-129088

Published: 2019

Journal Articles

Low Levels of Neurologic Toxicity with Retained Anti-Lymphoma Activity in a Phase I Clinical Trial of T Cells Expressing a Novel Anti-CD19 CAR

Jennifer Brudno, MD, Steven Hartman, Norris Lam, BS, David F. Stroncek, John M. Rossi, MS, Yueh-wei Shen, Allen Xue, PhD, Adrian Bot, MD PhD, Jennifer A Kanakry, MD, Steven Z. Pavletic, MD, Lekha Mikkilineni, MD, Mark Roschewski, MD, Robert M. Dean, MD, Jeremy J. Rose, MS, Rashmika Patel, Brenna Hansen, Steve A. Rosenberg, Ronald E. Gress, MD, James N. Kochenderfer, MD

Blood (2018) 132 (Supplement 1): 697.

https://doi.org/10.1182/blood-2018-99-113731

Published: 2018

Journal Articles

Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells are associated with clinical outcomes in NHL

John Rossi, Patrick Paczkowski, Yueh-Wei Shen, Kevin Morse, Brianna Flynn, Alaina Kaiser, Colin Ng, Kyle Gallatin, Tom Cain, Rong Fan, Sean Mackay, James R. Heath, Steven A. Rosenberg, James N. Kochenderfer, Jing Zhou, Adrian Bot

Blood (2018) 132 (8): 804–814.

https://doi.org/10.1182/blood-2018-01-828343

Published: 2018

Includes: Supplemental data

Journal Articles

Chimeric antigen receptor T-cell therapies for multiple myeloma

Lekha Mikkilineni, James N. Kochenderfer

Blood (2017) 130 (24): 2594–2602.

https://doi.org/10.1182/blood-2017-06-793869

Published: 2017

Journal Articles

Durable Clinical Responses in Heavily Pretreated Patients with Relapsed/Refractory Multiple Myeloma: Updated Results from a Multicenter Study of bb2121 Anti-Bcma CAR T Cell Therapy

Jesus G. Berdeja, MD, Yi Lin, MD PhD, Noopur Raje, MD, Nikhil Munshi, MD, David Siegel, MD PhD, Michaela Liedtke, MD, Sundar Jagannath, MD, Marcela V. Maus, MD PhD, Ashley Turka, Lyh Ping Lam, PharmD, RPh, Kristen Hege, MD, Richard A. Morgan, PhD, Michael Travis Quigley, James N. Kochenderfer, MD

Blood (2017) 130 (Supplement 1): 740.

https://doi.org/10.1182/blood.V130.Suppl_1.740.740

Published: 2017

Journal Articles

The Post-Thaw Recovery of Cryopreserved Chimeric Antigen Receptor (CAR) T-Cells during Manufacture Is Better Than That of Cryopreserved Peripheral Blood CD3+ Cells

Nasha Elavia, MD MBBS, Andrew McManus, Steven L Highfill, PhD, Jiaqiang Ren, MD PhD, Nirali N Shah, MD, Terry J. Fry, MD, Jennifer Brudno, MD, James N. Kochenderfer, MD, David Stroncek, MD, Sandhya R. Panch, MDMPH

Blood (2017) 130 (Supplement 1): 4475.

https://doi.org/10.1182/blood.V130.Suppl_1.4475.4475

Published: 2017

Journal Articles

T Cells Expressing Anti-B-Cell Maturation Antigen (BCMA) Chimeric Antigen Receptors with Antigen Recognition Domains Made up of Only Single Human Heavy Chain Variable Domains Specifically Recognize Bcma and Eradicate Tumors in Mice

Norris Lam, BS, Leah Alabanza, PhD, Nathan Trinklein, PhD, Ben Buelow, MD PhD, James N. Kochenderfer, MD

Blood (2017) 130 (Supplement 1): 504.

https://doi.org/10.1182/blood.V130.Suppl_1.504.504

Published: 2017

Journal Articles

T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor with a CD28 Costimulatory Moiety Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma

Jennifer Brudno, MD, Norris Lam, BS, Michael Wang, MD, David Stroncek, MD, Irina Maric, Maryalice Stetler-Stevenson, Constance Yuan, Steven Hartman, Jennifer A. Kanakry, MD, Steven Z. Pavletic, MD, Steven A. Feldman, Judith Lawrence, Rashmika Patel, Brenna Hansen, Ronald E. Gress, MD, James N. Kochenderfer, MD

Blood (2017) 130 (Supplement 1): 524.

https://doi.org/10.1182/blood.V130.Suppl_1.524.524

Published: 2017

Journal Articles

Long-Term Outcomes Following CD19 CAR T Cell Therapy for B-ALL Are Superior in Patients Receiving a Fludarabine/Cyclophosphamide Preparative Regimen and Post-CAR Hematopoietic Stem Cell Transplantation

Daniel W. Lee, III, MD, Maryalice Stetler-Stevenson, MD PhD, Constance M. Yuan, MD PhD, Nirali N Shah, MD, Cindy Delbrook, RN, Bonnie Yates, RN, PNP, Hua Zhang, PhD, Ling Zhang, PhD, James N. Kochenderfer, MD, Steven A. Rosenberg, MD PhD, Terry J Fry, MD, David Stroncek, MD, Crystal L. Mackall, MD

Blood (2016) 128 (22): 218.

https://doi.org/10.1182/blood.V128.22.218.218

Published: 2016

Journal Articles

T Cells Expressing a Novel Fully-Human Anti-CD19 Chimeric Antigen Receptor Induce Remissions of Advanced Lymphoma in a First-in-Humans Clinical Trial

Jennifer N. Brudno, MD, Victoria Shi, David Stroncek, MD, Stefania Pittaluga, MD PhD, Jennifer A. Kanakry, MD, Lauren M. Curtis, MD, Juan C. Gea-Banacloche, MD, Steven Pavletic, MD, Mohammad-Hadi Bagheri, MD, Jeremy J. Rose, MS, Rashmika Patel, Brenna Hansen, Ronald E. Gress, MD, James N. Kochenderfer, MD

Blood (2016) 128 (22): 999.

https://doi.org/10.1182/blood.V128.22.999.999

Published: 2016

NARROW

Development of Novel Chimeric Antigen Receptors Targeting the Gamma-Delta (γδ) T-Cell Receptor

Adoptive Transfer of T Cells Genetically Engineered to Express T-Cell Receptors Targeting Neoantigens Arising from p53 and Ras Hotspot Mutations in Hematologic Malignancies

Generation of Hinge-Modified Human CD19 Chimeric Antigen Receptor (CAR) T Cells for the Treatment of CD19-Low Leukemia

T Cells Expressing a Fully-Human Anti-BCMA Chimeric Antigen Receptor with a Heavy-Chain-Only Antigen-Recognition Domain Exhibit Rapid and Durable Activity Against Multiple Myeloma

Transient Responses and Significant Toxicities Due to Cytopenias and Rashes with Anti-CD30 CAR T Cells for CD30-Expressing Lymphomas: Results of a Phase I Clinical Trial

Treatment of Patients with T Cells Expressing a Fully-Human Anti-BCMA CAR with a Heavy-Chain Antigen-Recognition Domain Caused High Rates of Sustained Complete Responses and Relatively Mild Toxicity

Development of a Bicistronic Anti-CD19/CD20 CAR Construct Including Optimization to Abrogate Retroviral Recombination Events

Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy, in Patients with Relapsed and Refractory Multiple Myeloma: Updated Results from Phase 1 CRB-401 Study

Deep and Durable Remissions of Relapsed Multiple Myeloma on a First-in-Humans Clinical Trial of T Cells Expressing an Anti-B-Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor (CAR) with a Fully-Human Heavy-Chain-Only Antigen Recognition Domain

Infectious Complications Associated with CAR T-Cell Therapy

T Cells Expressing an Anti-B-Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor with a Fully-Human Heavy-Chain-Only Antigen Recognition Domain Induce Remissions in Patients with Relapsed Multiple Myeloma

Low Levels of Neurologic Toxicity with Retained Anti-Lymphoma Activity in a Phase I Clinical Trial of T Cells Expressing a Novel Anti-CD19 CAR

Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells are associated with clinical outcomes in NHL

Chimeric antigen receptor T-cell therapies for multiple myeloma

Durable Clinical Responses in Heavily Pretreated Patients with Relapsed/Refractory Multiple Myeloma: Updated Results from a Multicenter Study of bb2121 Anti-Bcma CAR T Cell Therapy

The Post-Thaw Recovery of Cryopreserved Chimeric Antigen Receptor (CAR) T-Cells during Manufacture Is Better Than That of Cryopreserved Peripheral Blood CD3+ Cells

T Cells Expressing Anti-B-Cell Maturation Antigen (BCMA) Chimeric Antigen Receptors with Antigen Recognition Domains Made up of Only Single Human Heavy Chain Variable Domains Specifically Recognize Bcma and Eradicate Tumors in Mice

T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor with a CD28 Costimulatory Moiety Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma

Long-Term Outcomes Following CD19 CAR T Cell Therapy for B-ALL Are Superior in Patients Receiving a Fludarabine/Cyclophosphamide Preparative Regimen and Post-CAR Hematopoietic Stem Cell Transplantation

T Cells Expressing a Novel Fully-Human Anti-CD19 Chimeric Antigen Receptor Induce Remissions of Advanced Lymphoma in a First-in-Humans Clinical Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only